Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Genome editing of human pancreatic beta cell models: problems, possibilities and outlook

  • Balboa, Diego
  • Prasad, Rashmi B.
  • Groop, Leif
  • Otonkoski, Timo
Understanding the molecular mechanisms behind beta cell dysfunction is essential for the development of effective and specific approaches for diabetes care and prevention. Physiological human beta cell models are needed for this work. We review the possibilities and limitations of currently available human beta cell models and how they can be dramatically enhanced using genome-editing technologies. In addition to the gold standard, primary isolated islets, other models now include immortalised human beta cell lines and pluripotent stem cell-derived islet-like cells. The scarcity of human primary islet samples limits their use, but valuable gene expression and functional data from large collections of human islets have been made available to the scientific community. The possibilities for studying beta cell physiology using immortalised human beta cell lines and stem cell-derived islets are rapidly evolving. However, the functional immaturity of these cells is still a significant limitation. CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9) has enabled precise engineering of specific genetic variants, targeted transcriptional modulation and genome-wide genetic screening. These approaches can now be exploited to gain understanding of the mechanisms behind coding and non-coding diabetes-associated genetic variants, allowing more precise evaluation of their contribution to diabetes pathogenesis. Despite all the progress, genome editing in primary pancreatic islets remains difficult to achieve, an important limitation requiring further technological development., The authors’ work in this area has been supported by grants from the Academy of Finland, The Novo Nordisk Foundation and the Sigrid Jusélius Foundation. TO is also funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115797 (INNODIA), which receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA), JDRF and the Leona M. and Harry B. Helmsley Charitable Trust.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

An integrated multi-omics approach identifies the landscape of interferon-α-mediated responses of human pancreatic beta cells

  • Colli, Maikel Luis
  • Ramos-Rodríguez, Mireia
  • Raurell Vila, Helena
  • Pasquali, Lorenzo
  • Eizirik, Décio L.
Interferon-α (IFNα), a type I interferon, is expressed in the islets of type 1 diabetic individuals, and its expression and signaling are regulated by T1D genetic risk variants and viral infections associated with T1D. We presently characterize human beta cell responses to IFNα by combining ATAC-seq, RNA-seq and proteomics assays. The initial response to IFNα is characterized by chromatin remodeling, followed by changes in transcriptional and translational regulation. IFNα induces changes in alternative splicing (AS) and first exon usage, increasing the diversity of transcripts expressed by the beta cells. This, combined with changes observed on protein modification/degradation, ER stress and MHC class I, may expand antigens presented by beta cells to the immune system. Beta cells also up-regulate the checkpoint proteins PDL1 and HLA-E that may exert a protective role against the autoimmune assault. Data mining of the present multi-omics analysis identifies two compound classes that antagonize IFNα effects on human beta cells., This work was supported by grants from the Fonds National de la Recherche Scientifique (FNRS), Welbio CR-2015A-06 and CR-2019C-04, Belgium; the Horizon 2020 Program, T2Dsystems (GA667191); the National Institutes of Health, NIH-NIDDK-HIRN Consortium 1UC4DK104166-01 and Innovate2CureType1 - Dutch Diabetes Research Fundation (DDRF). D.L.E. and P.M. have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 115797 (INNODIA). This Joint Undertaking receives support from the Union’s Horizon 2020 research and innovation programme and “EFPIA”, “JDRF” and “The Leona M. and Harry B. Helmsley Charitable Trust”. The DiViD study is funded by The South-Eastern Norway Regional Health Authority (grant to K.D.-J.), the Novo Nordisk Foundation (grant to K.D.-J.), and through the PEVNET (Persistent Virus Infection in Diabetes Network) Study Group funded by the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant Agreement Number 261441 PEVNET. Additional support was from a JDRF Career Development Award (5-CDA-2014-221-A-N) to S.J.R., a JDRF research grant awarded to the network of Pancreatic Organ Donors – Virus (nPOD-V) consortium (JDRF 25-2012-516); an MRC Project Grant MR/P010695/1 awarded to S.J.R. and N.G.M., a studentship grant from the Norman Family Trust (to S.J.R. and N.G.M.), a Spanish Ministry of Economy and Competiveness (SAF2017-86242-R to L.P.) and Marató TV3 (201624.10 to L.P.). L.P. is a recipient of a Ramon y Cajal contract from the Spanish Ministry of Economy and Competitiveness (RYC-2013-12864) and M.R. is supported by an FI Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) PhD fellowship.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The impact of proinflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of type 1 diabetes

  • Ramos-Rodríguez, Mireia
  • Raurell Vila, Helena
  • Colli, Maikel Luis
  • Alvelos, Maria Inês
  • Subirana-Granés, Marc
  • Juan-Mateu, Jonàs
  • Norris, Richard
  • Turatsinze, Jean-Valery
  • Nakayasu, Ernesto S.
  • Webb-Robertson, Bobbie-Jo M.
  • Inshaw, Jamie R. J.
  • Marchetti, Piero
  • Piemonti, Lorenzo
  • Esteller, Manel
  • Todd, John A.
  • Metz, Thomas O.
  • Eizirik, Décio L.
  • Pasquali, Lorenzo
The early stages of type 1 diabetes (T1D) are characterized by local autoimmune inflammation and progressive loss of insulin-producing pancreatic β cells. Here we show that exposure to proinflammatory cytokines reveals a marked plasticity of the β-cell regulatory landscape. We expand the repertoire of human islet regulatory elements by mapping stimulus-responsive enhancers linked to changes in the β-cell transcriptome, proteome and three-dimensional chromatin structure. Our data indicate that the β-cell response to cytokines is mediated by the induction of new regulatory regions as well as the activation of primed regulatory elements prebound by islet-specific transcription factors. We find that T1D-associated loci are enriched with newly mapped cis-regulatory regions and identify T1D-associated variants disrupting cytokine-responsive enhancer activity in human β cells. Our study illustrates how β cells respond to a proinflammatory environment and implicate a role for stimulus response islet enhancers in T1D., L.Pasquali was supported by grants from the Spanish Ministry of Economy and Competitiveness (nos. BFU2014-58150-R and SAF2017-86242-R), Marató TV3 (no. 201624.10) and a young investigator award from the Spanish Society of Diabetes (Ayuda SED a Proyectos de Investigación, no. 2017-SED). L.Pasquali is a recipient of a Ramon y Cajal contract from the Spanish Ministry of Economy and Competitiveness (no. RYC-2013-12864). The Pasquali lab is further supported by Instituto de Salud Carlos III (no. PIE16/00011). M.R. is supported by an FI Agència de Gestió d’Ajuts Universitaris i de Recerca PhD fellowship (no. 2019FI_B100203). J.J. was supported by a Marie Skłodowska-Curie Actions fellowship grant from the Horizons 2020 European Union (EU) Programme (project no. 660449). M.I.A. was supported by a FRIA fellowship from the Fonds de la Recherche Scientifique (FNRS) (no. 26410496). Human islets were provided through the European Consortium for Islet Transplantation distribution program for basic research supported by JDRF (no. 31-2008-416). D.L.E. was supported by the Walloon Region through the FRFS-WELBIO Fund for Strategic Fundamental research (no. CR-2015A-06s and CR-2019C-04) and by grants from the Fonds National de la Recherche Scientifique (no. T003613F), the Horizon 2020 Programme (project T2Dsystems, no. GA667191), Brussels Capital Region Innoviris (project DiaType, no. 2017-PFS-24), Dutch Diabetes Research Fundation (project Innovate2CureType1, DDRF; no. 2018.10.002) and the Innovative Medicines Initiative 2 Joint Undertaking (project INNODIA, no. 115797). This Innovative Medicines Initiative 2 Joint Undertaking receives support from the EU’s Horizon 2020 Research and Innovation Programme and European Federation of Pharmaceutical Industries and Associations, JDRF and the Leona M. and Harry B. Helmsley Charitable Trust (project INNODIA, no. 115797). T.O.M. and D.L.E. were supported by a grant from the National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases-Human Islet Research Network Consortium (no. 1UC4DK104166-01). Part of the work was performed at the Environmental Molecular Sciences Laboratory, a US Department of Energy national scientific user facility located at Pacific Northwest National Laboratory. Battelle operates the Pacific Northwest National Laboratory for the Department of Energy (contract no. DE-AC05-76RLO01830).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The type 1 diabetes gene TYK2 regulates β-cell development and its responses to interferon-α

  • Chandra, Vikash
  • Ibrahim, Hazem
  • Halliez, Clémentine
  • Prasad, Rashmi B.
  • Vecchio, Federica
  • Dwivedi, Om Prakash
  • Kvist, Jouni
  • Balboa, Diego
  • Saarimäki-Vire, Jonna
  • Montaser, Hossam
  • Barsby, Tom
  • Lithovius, Väinö
  • Artner, Isabella
  • Gopalakrishnan, Swetha
  • Groop, Leif
  • Mallone, Roberto
  • Eizirik, Décio L.
  • Otonkoski, Timo
Type 1 diabetes (T1D) is an autoimmune disease that results in the destruction of insulin producing pancreatic β-cells. One of the genes associated with T1D is TYK2, which encodes a Janus kinase with critical roles in type-Ι interferon (IFN-Ι) mediated intracellular signalling. To study the role of TYK2 in β-cell development and response to IFNα, we generated TYK2 knockout human iPSCs and directed them into the pancreatic endocrine lineage. Here we show that loss of TYK2 compromises the emergence of endocrine precursors by regulating KRAS expression, while mature stem cell-islets (SC-islets) function is not affected. In the SC-islets, the loss or inhibition of TYK2 prevents IFNα-induced antigen processing and presentation, including MHC Class Ι and Class ΙΙ expression, enhancing their survival against CD8+ T-cell cytotoxicity. These results identify an unsuspected role for TYK2 in β-cell development and support TYK2 inhibition in adult β-cells as a potent therapeutic target to halt T1D progression., We gratefully acknowledge Dr. Fatoumata Samassa for help with cytotoxicity assays. We thank Jarkko Ustinov for the insulin and c-peptide ELISA measurements. S. Eurola, H. Grym, and A. Laitinen are thanked for expert technical support. We thank FIMM Single Cell Analytics unit (supported by HiLIFE and Biocentre Finland) for single cell RNA sequencing services. We want to acknowledge the participants and investigators of the FinnGen study. T.O. acknowledges the funding provided by the Academy of Finland (MetaStem Center of Excellence grant 312437), the Novo Nordisk Foundation and the Sigrid Juselius Foundation. R.M. acknowledges the support of the Agence Nationale de la Recherche (ANR-19-CE15-0014-01) and the Fondation pour la Recherche Medicale (EQU20193007831). C.H. was funded by an Année Recherche fellowship of the Paris Saclay University. F.V. was funded by an international PhD fellowship of the IdEx Université de Paris. R.B.P. acknowledges the funding by Hjelt foundation, Crafoord foundation (2020089) and Swedish Research Council (2021-02623). D.L.E. acknowledges the support of grants from the Welbio-FNRS (Fonds National de la Recherche Scientifique; WELBIO-CR-2019C-04), Belgium; the Innovate2CureType1—Dutch Diabetes Research Foundation (DDRF), Holland; the Juvenile Diabetes Foundation (JDRF; 2-SRA-2019-834-S-B); the NIH (HIRN-CBDS) grant U01 DK127786, USA. D.L.E., T.O., and R.M. acknowledge support from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements No 115797 (INNODIA) and 945268 (INNODIA HARVEST), supported by the European Union’s Horizon 2020 research and innovation programme. These Joint Undertakings receive support from the Union’s Horizon 2020 research and innovation programme and “EFPIA”, “JDRF” and “The Leona M. and Harry B. Helmsley Charitable Trust”.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rheological Behavior of Oil Well Cement Slurries with Addition of Core/Shell TiO2@SiO2 Nanoparticles—Effect of Superplasticizer and Temperature

  • Batista, Giovanni dos Santos
  • Puertas, Francisca
  • Takimi, Antonio Shigueaki
  • Costa, Eleani Maria da
  • Palacios, Marta
This study investigates the rheological behavior of oil well cement pastes (OWCPs) modified with core/shell TiO2@SiO2 (nTS) nanoparticles and polycarboxylate-ether (PCE) superplasticizers at different temperatures (25, 45, and 60 °C). Results show that nTS particles increased static and dynamic yield stresses and the apparent viscosity of the cement slurries due to an increased solid volume fraction and reduced free water availability. The increase in the slurry dispersion by adding PCE superplasticizers enhanced the effect of the nanoparticles on the rheological parameters. Oscillation rheometry demonstrated that nTS nanoparticles enhanced the structural buildup, while PCE retarded hydration. Furthermore, slurries hydrated at 60 °C experienced higher initial values of the elastic modulus and a faster exponential increase in this rheological parameter due to the acceleration of the cement hydration., This research was partly funded by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES), grant number 001 and PID2020-115797RB-I00/AEI/10.13039/501100011033 (RHEODUR) project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impact of pore solution composition and superplasticizers on the interparticle forces and rheology of metakaolin suspensions

  • Real, Sergio
  • Bowen, Paul
  • Moreno, Rodrigo
  • González-Panicello, Laura
  • Puertas, Francisca
  • Hanafi, Mohamed
  • Palacios, Marta
This study focuses on the influence of pH, aqueous phase composition and superplasticizers on the particle interactions in pure metakaolin suspensions. It was found increasing pH up to 11 led to the decrease of the particle agglomeration due to the higher OH− adsorption onto metakaolin particles, which increased the absolute zeta potential and generates higher electrostatic repulsive forces. Above pH = 11, a slight increase in zeta potential was observed and colloidal stability was retained. Metakaolin suspensions prepared in Na2SO4 or Ca(OH)2 at pH = 13 did not agglomerate. However, the simultaneous presence of Ca2+ and SO42−, led to particle agglomeration, which was enhanced as Ca2+ concentration increased. The rise of Ca2+ concentration in suspensions containing Ca2+ and SO42− also induced higher yield stress values in metakaolin suspensions. The addition of polycarboxylate ether (PCE) superplasticizers deagglomerated metakaolin particles and decreased yield stress values in agreement with interparticle force modelling., Authors thank PID2020-115797RB-I00/ AEI/10.13039/501100011033 (RHEODUR) project. C. Alcázar from ICV-CSIC is thanked for her help during the zeta potential measurements. Dr. Lukas Frunz (Sika Technology AG) is thanked for the synthesis of the PCEs., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evolution of the microstructure of limestone-calcined clay cement pastes exposed to CO2

  • Pachón Montaño, Alicia
  • González-Panicello, Laura
  • Alonso, M. Cruz
  • Puertas, Francisca
  • Roig-Flores, M.
  • Palacios, Marta
The datasets generated and analyzed during the current study are available in the DIGITAL.CSIC repository, https://doi.org/10.20350/digitalCSIC/18511., The aim of this study was to gain a deeper understanding of the carbonation resistance of binary and ternary calcined clay-blended cements, and to investigate how this resistance correlates with their microstructure and phase assemblage. A lower carbonation resistance was observed for calcined clay-containing cement pastes compared to OPC, which can be attributed to their lower contents of CaO reactive and portlandite. Keeping constant the clinker content of the blend, in limestone-calcined clay cements (LC<sup>3</sup>) pastes, the increase of the amount of metakaolin increased their carbonation resistance. Additionally, the presence of limestone in the ternary blends, which promotes the formation of carboaluminate phases, appears to play a positive role in enhancing the carbonation resistance of the calcined clay-blended cements. After 6 months of exposure of the pastes to 1 wt% CO<inf>2</inf>, C-A-S-H formed in calcined clay blended cements suffered a substantial decomposition, leading to the formation of an aluminosilicate gel and a coarsening of the pore structure. In contrast, no significant decomposition of C-A-S-H was observed in the OPC pastes under the same conditions. Regarding the CaCO<inf>3</inf> polymorphism, calcite was the major polymorphism formed in all cases, although vaterite was also identified in both the binary and ternary calcined clay-blended cements., Grants PID2020\u2013115797RB-I00 and PID2023\u2013149927OB-I00 funded by MICIU / AEI / 10.13039/501100011033 and MICIU/AEI/ 10.13039/501100011033/FEDER , UE, respectively., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

An integrated multi-omics approach identifies the landscape of interferon-α-mediated responses of human pancreatic beta cells

  • Colli, Maikel Luis
  • Ramos-Rodríguez, Mireia
  • Raurell Vila, Helena
  • Pasquali, Lorenzo
  • Eizirik, Décio L.
Interferon-α (IFNα), a type I interferon, is expressed in the islets of type 1 diabetic individuals, and its expression and signaling are regulated by T1D genetic risk variants and viral infections associated with T1D. We presently characterize human beta cell responses to IFNα by combining ATAC-seq, RNA-seq and proteomics assays. The initial response to IFNα is characterized by chromatin remodeling, followed by changes in transcriptional and translational regulation. IFNα induces changes in alternative splicing (AS) and first exon usage, increasing the diversity of transcripts expressed by the beta cells. This, combined with changes observed on protein modification/degradation, ER stress and MHC class I, may expand antigens presented by beta cells to the immune system. Beta cells also up-regulate the checkpoint proteins PDL1 and HLA-E that may exert a protective role against the autoimmune assault. Data mining of the present multi-omics analysis identifies two compound classes that antagonize IFNα effects on human beta cells., This work was supported by grants from the Fonds National de la Recherche Scientifique (FNRS), Welbio CR-2015A-06 and CR-2019C-04, Belgium; the Horizon 2020 Program, T2Dsystems (GA667191); the National Institutes of Health, NIH-NIDDK-HIRN Consortium 1UC4DK104166-01 and Innovate2CureType1 - Dutch Diabetes Research Fundation (DDRF). D.L.E. and P.M. have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 115797 (INNODIA). This Joint Undertaking receives support from the Union’s Horizon 2020 research and innovation programme and “EFPIA”, “JDRF” and “The Leona M. and Harry B. Helmsley Charitable Trust”. The DiViD study is funded by The South-Eastern Norway Regional Health Authority (grant to K.D.-J.), the Novo Nordisk Foundation (grant to K.D.-J.), and through the PEVNET (Persistent Virus Infection in Diabetes Network) Study Group funded by the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant Agreement Number 261441 PEVNET. Additional support was from a JDRF Career Development Award (5-CDA-2014-221-A-N) to S.J.R., a JDRF research grant awarded to the network of Pancreatic Organ Donors – Virus (nPOD-V) consortium (JDRF 25-2012-516); an MRC Project Grant MR/P010695/1 awarded to S.J.R. and N.G.M., a studentship grant from the Norman Family Trust (to S.J.R. and N.G.M.), a Spanish Ministry of Economy and Competiveness (SAF2017-86242-R to L.P.) and Marató TV3 (201624.10 to L.P.). L.P. is a recipient of a Ramon y Cajal contract from the Spanish Ministry of Economy and Competitiveness (RYC-2013-12864) and M.R. is supported by an FI Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) PhD fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genome editing of human pancreatic beta cell models: problems, possibilities and outlook

  • Balboa, Diego
  • Prasad, Rashmi B.
  • Groop, Leif
  • Otonkoski, Timo
Understanding the molecular mechanisms behind beta cell dysfunction is essential for the development of effective and specific approaches for diabetes care and prevention. Physiological human beta cell models are needed for this work. We review the possibilities and limitations of currently available human beta cell models and how they can be dramatically enhanced using genome-editing technologies. In addition to the gold standard, primary isolated islets, other models now include immortalised human beta cell lines and pluripotent stem cell-derived islet-like cells. The scarcity of human primary islet samples limits their use, but valuable gene expression and functional data from large collections of human islets have been made available to the scientific community. The possibilities for studying beta cell physiology using immortalised human beta cell lines and stem cell-derived islets are rapidly evolving. However, the functional immaturity of these cells is still a significant limitation. CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9) has enabled precise engineering of specific genetic variants, targeted transcriptional modulation and genome-wide genetic screening. These approaches can now be exploited to gain understanding of the mechanisms behind coding and non-coding diabetes-associated genetic variants, allowing more precise evaluation of their contribution to diabetes pathogenesis. Despite all the progress, genome editing in primary pancreatic islets remains difficult to achieve, an important limitation requiring further technological development., The authors’ work in this area has been supported by grants from the Academy of Finland, The Novo Nordisk Foundation and the Sigrid Jusélius Foundation. TO is also funded by the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 115797 (INNODIA), which receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA), JDRF and the Leona M. and Harry B. Helmsley Charitable Trust.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The type 1 diabetes gene TYK2 regulates β-cell development and its responses to interferon-α

  • Chandra, Vikash
  • Ibrahim, Hazem
  • Halliez, Clémentine
  • Prasad, Rashmi B.
  • Vecchio, Federica
  • Dwivedi, Om Prakash
  • Kvist, Jouni
  • Balboa, Diego
  • Saarimäki-Vire, Jonna
  • Montaser, Hossam
  • Barsby, Tom
  • Lithovius, Väinö
  • Artner, Isabella
  • Gopalakrishnan, Swetha
  • Groop, Leif
  • Mallone, Roberto
  • Eizirik, Décio L.
  • Otonkoski, Timo
Type 1 diabetes (T1D) is an autoimmune disease that results in the destruction of insulin producing pancreatic β-cells. One of the genes associated with T1D is TYK2, which encodes a Janus kinase with critical roles in type-Ι interferon (IFN-Ι) mediated intracellular signalling. To study the role of TYK2 in β-cell development and response to IFNα, we generated TYK2 knockout human iPSCs and directed them into the pancreatic endocrine lineage. Here we show that loss of TYK2 compromises the emergence of endocrine precursors by regulating KRAS expression, while mature stem cell-islets (SC-islets) function is not affected. In the SC-islets, the loss or inhibition of TYK2 prevents IFNα-induced antigen processing and presentation, including MHC Class Ι and Class ΙΙ expression, enhancing their survival against CD8+ T-cell cytotoxicity. These results identify an unsuspected role for TYK2 in β-cell development and support TYK2 inhibition in adult β-cells as a potent therapeutic target to halt T1D progression., We gratefully acknowledge Dr. Fatoumata Samassa for help with cytotoxicity assays. We thank Jarkko Ustinov for the insulin and c-peptide ELISA measurements. S. Eurola, H. Grym, and A. Laitinen are thanked for expert technical support. We thank FIMM Single Cell Analytics unit (supported by HiLIFE and Biocentre Finland) for single cell RNA sequencing services. We want to acknowledge the participants and investigators of the FinnGen study. T.O. acknowledges the funding provided by the Academy of Finland (MetaStem Center of Excellence grant 312437), the Novo Nordisk Foundation and the Sigrid Juselius Foundation. R.M. acknowledges the support of the Agence Nationale de la Recherche (ANR-19-CE15-0014-01) and the Fondation pour la Recherche Medicale (EQU20193007831). C.H. was funded by an Année Recherche fellowship of the Paris Saclay University. F.V. was funded by an international PhD fellowship of the IdEx Université de Paris. R.B.P. acknowledges the funding by Hjelt foundation, Crafoord foundation (2020089) and Swedish Research Council (2021-02623). D.L.E. acknowledges the support of grants from the Welbio-FNRS (Fonds National de la Recherche Scientifique; WELBIO-CR-2019C-04), Belgium; the Innovate2CureType1—Dutch Diabetes Research Foundation (DDRF), Holland; the Juvenile Diabetes Foundation (JDRF; 2-SRA-2019-834-S-B); the NIH (HIRN-CBDS) grant U01 DK127786, USA. D.L.E., T.O., and R.M. acknowledge support from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreements No 115797 (INNODIA) and 945268 (INNODIA HARVEST), supported by the European Union’s Horizon 2020 research and innovation programme. These Joint Undertakings receive support from the Union’s Horizon 2020 research and innovation programme and “EFPIA”, “JDRF” and “The Leona M. and Harry B. Helmsley Charitable Trust”.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The impact of proinflammatory cytokines on the β-cell regulatory landscape provides insights into the genetics of type 1 diabetes

  • Ramos-Rodríguez, Mireia
  • Raurell Vila, Helena
  • Colli, Maikel Luis
  • Alvelos, Maria Inês
  • Subirana-Granés, Marc
  • Juan-Mateu, Jonàs
  • Norris, Richard
  • Turatsinze, Jean-Valery
  • Nakayasu, Ernesto S.
  • Webb-Robertson, Bobbie-Jo M.
  • Inshaw, Jamie R. J.
  • Marchetti, Piero
  • Piemonti, Lorenzo
  • Esteller, Manel
  • Todd, John A.
  • Metz, Thomas O.
  • Eizirik, Décio L.
  • Pasquali, Lorenzo
The early stages of type 1 diabetes (T1D) are characterized by local autoimmune inflammation and progressive loss of insulin-producing pancreatic β cells. Here we show that exposure to proinflammatory cytokines reveals a marked plasticity of the β-cell regulatory landscape. We expand the repertoire of human islet regulatory elements by mapping stimulus-responsive enhancers linked to changes in the β-cell transcriptome, proteome and three-dimensional chromatin structure. Our data indicate that the β-cell response to cytokines is mediated by the induction of new regulatory regions as well as the activation of primed regulatory elements prebound by islet-specific transcription factors. We find that T1D-associated loci are enriched with newly mapped cis-regulatory regions and identify T1D-associated variants disrupting cytokine-responsive enhancer activity in human β cells. Our study illustrates how β cells respond to a proinflammatory environment and implicate a role for stimulus response islet enhancers in T1D., L.Pasquali was supported by grants from the Spanish Ministry of Economy and Competitiveness (nos. BFU2014-58150-R and SAF2017-86242-R), Marató TV3 (no. 201624.10) and a young investigator award from the Spanish Society of Diabetes (Ayuda SED a Proyectos de Investigación, no. 2017-SED). L.Pasquali is a recipient of a Ramon y Cajal contract from the Spanish Ministry of Economy and Competitiveness (no. RYC-2013-12864). The Pasquali lab is further supported by Instituto de Salud Carlos III (no. PIE16/00011). M.R. is supported by an FI Agència de Gestió d’Ajuts Universitaris i de Recerca PhD fellowship (no. 2019FI_B100203). J.J. was supported by a Marie Skłodowska-Curie Actions fellowship grant from the Horizons 2020 European Union (EU) Programme (project no. 660449). M.I.A. was supported by a FRIA fellowship from the Fonds de la Recherche Scientifique (FNRS) (no. 26410496). Human islets were provided through the European Consortium for Islet Transplantation distribution program for basic research supported by JDRF (no. 31-2008-416). D.L.E. was supported by the Walloon Region through the FRFS-WELBIO Fund for Strategic Fundamental research (no. CR-2015A-06s and CR-2019C-04) and by grants from the Fonds National de la Recherche Scientifique (no. T003613F), the Horizon 2020 Programme (project T2Dsystems, no. GA667191), Brussels Capital Region Innoviris (project DiaType, no. 2017-PFS-24), Dutch Diabetes Research Fundation (project Innovate2CureType1, DDRF; no. 2018.10.002) and the Innovative Medicines Initiative 2 Joint Undertaking (project INNODIA, no. 115797). This Innovative Medicines Initiative 2 Joint Undertaking receives support from the EU’s Horizon 2020 Research and Innovation Programme and European Federation of Pharmaceutical Industries and Associations, JDRF and the Leona M. and Harry B. Helmsley Charitable Trust (project INNODIA, no. 115797). T.O.M. and D.L.E. were supported by a grant from the National Institutes of Health-National Institute of Diabetes and Digestive and Kidney Diseases-Human Islet Research Network Consortium (no. 1UC4DK104166-01). Part of the work was performed at the Environmental Molecular Sciences Laboratory, a US Department of Energy national scientific user facility located at Pacific Northwest National Laboratory. Battelle operates the Pacific Northwest National Laboratory for the Department of Energy (contract no. DE-AC05-76RLO01830).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

An integrated multi-omics approach identifies the landscape of interferon-α-mediated responses of human pancreatic beta cells

  • Colli, Maikel L.|||0000-0002-2200-4761
  • Ramos Rodríguez, Mireia|||0000-0001-8083-2445
  • Nakayasu, Ernesto S.|||0000-0002-4056-2695
  • Alvelos, Maria I.
  • Lopes, Miguel
  • Hill, Jessica L. E.
  • Turatsinze, Jean-Valery|||0000-0001-9492-6274
  • Coomans de Brachène, Alexandra
  • Russell, Mark A.
  • Raurell Vila, Helena|||0000-0003-1196-836X
  • Castela, Angela
  • Juan-Mateu, Jonàs
  • Webb-Robertson, Bobbie-Jo M.
  • Krogvold, Lars
  • Dahl-Jorgensen, Knut
  • Marselli, Lorella|||0000-0002-6698-2962
  • Marchetti, Piero
  • Richardson, Sarah J.|||0000-0002-1160-6062
  • Morgan, Noel G.|||0000-0003-1537-8113
  • Metz, Thomas O.|||0000-0001-6049-3968
  • Pasquali, Lorenzo|||0000-0003-2423-1826
  • Eizirik, Décio L.|||0000-0003-2453-5889
Interferon-α (IFNα), a type I interferon, is expressed in the islets of type 1 diabetic individuals, and its expression and signaling are regulated by T1D genetic risk variants and viral infections associated with T1D. We presently characterize human beta cell responses to IFNα by combining ATAC-seq, RNA-seq and proteomics assays. The initial response to IFNα is characterized by chromatin remodeling, followed by changes in transcriptional and translational regulation. IFNα induces changes in alternative splicing (AS) and first exon usage, increasing the diversity of transcripts expressed by the beta cells. This, combined with changes observed on protein modification/degradation, ER stress and MHC class I, may expand antigens presented by beta cells to the immune system. Beta cells also up-regulate the checkpoint proteins PDL1 and HLA-E that may exert a protective role against the autoimmune assault. Data mining of the present multi-omics analysis identifies two compound classes that antagonize IFNα effects on human beta cells.